Cargando…

Positive effects of the progestin desogestrel 75 μg on migraine frequency and use of acute medication are sustained over a treatment period of 180 days

BACKGROUND: Premenopausal migraines frequently are associated with fluctuations of estrogen levels. Both, migraine and combined hormonal contraceptives (CHC) increase the risk of vascular events. Therefore progestagen-only contraceptives (POC) are a safer alternative. A previous short-term study dem...

Descripción completa

Detalles Bibliográficos
Autores principales: Merki-Feld, Gabriele S, Imthurn, Bruno, Langner, Ronald, Seifert, Burkhardt, Gantenbein, Andreas R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4420760/
https://www.ncbi.nlm.nih.gov/pubmed/25933634
http://dx.doi.org/10.1186/s10194-015-0522-8
_version_ 1782369759811076096
author Merki-Feld, Gabriele S
Imthurn, Bruno
Langner, Ronald
Seifert, Burkhardt
Gantenbein, Andreas R
author_facet Merki-Feld, Gabriele S
Imthurn, Bruno
Langner, Ronald
Seifert, Burkhardt
Gantenbein, Andreas R
author_sort Merki-Feld, Gabriele S
collection PubMed
description BACKGROUND: Premenopausal migraines frequently are associated with fluctuations of estrogen levels. Both, migraine and combined hormonal contraceptives (CHC) increase the risk of vascular events. Therefore progestagen-only contraceptives (POC) are a safer alternative. A previous short-term study demonstrated a positive impact of the oral POC desogestrel on migraine frequency. To study the effect of the POC desogestrel 75 μg on migraine frequency, intensity, use of acute medication and quality of life in a clinical setting over the period of 180 days. METHODS: Patients’ charts were screened for women with migraine, who had decided to use desogestrel for contraception. Charts were included, if routinely conducted headache diaries were complete for 90 days before treatment (baseline) and over a treatment period of 180 days. We also report about starters who stopped treatment early, because of adverse events. Baseline data (day 1–90 before treatment) were compared with first and second treatment period (treatment days 1–90 and days 91–180). Quality of life was evaluated using MIDAS questionnaires. RESULTS: Days with migraine (5.8 vs 3.6), with any kind of headache (9.4 vs 6.6), headache intensity (15.7 vs 10.7), days with severe headache (5.4 vs 2.4) and use of triptans (12.3 vs7.8) were significantly reduced after 180 days. MIDAS score and grade improved significantly. CONCLUSION: Contraception with desogestrel 75 μg resulted in a significantly improved quality of life and a reduction of migraine days over the observation period of 180 days. A clinically meaningful 30% reduction in pain was observed in 25/42 (60%) participants. For counselling reasons it is of importance, that the major reduction in migraine frequency occured during the initial 90 days, however further improvement occurs with longer duration of use. Prospective studies are needed to confirm these results.
format Online
Article
Text
id pubmed-4420760
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Milan
record_format MEDLINE/PubMed
spelling pubmed-44207602015-05-14 Positive effects of the progestin desogestrel 75 μg on migraine frequency and use of acute medication are sustained over a treatment period of 180 days Merki-Feld, Gabriele S Imthurn, Bruno Langner, Ronald Seifert, Burkhardt Gantenbein, Andreas R J Headache Pain Research Article BACKGROUND: Premenopausal migraines frequently are associated with fluctuations of estrogen levels. Both, migraine and combined hormonal contraceptives (CHC) increase the risk of vascular events. Therefore progestagen-only contraceptives (POC) are a safer alternative. A previous short-term study demonstrated a positive impact of the oral POC desogestrel on migraine frequency. To study the effect of the POC desogestrel 75 μg on migraine frequency, intensity, use of acute medication and quality of life in a clinical setting over the period of 180 days. METHODS: Patients’ charts were screened for women with migraine, who had decided to use desogestrel for contraception. Charts were included, if routinely conducted headache diaries were complete for 90 days before treatment (baseline) and over a treatment period of 180 days. We also report about starters who stopped treatment early, because of adverse events. Baseline data (day 1–90 before treatment) were compared with first and second treatment period (treatment days 1–90 and days 91–180). Quality of life was evaluated using MIDAS questionnaires. RESULTS: Days with migraine (5.8 vs 3.6), with any kind of headache (9.4 vs 6.6), headache intensity (15.7 vs 10.7), days with severe headache (5.4 vs 2.4) and use of triptans (12.3 vs7.8) were significantly reduced after 180 days. MIDAS score and grade improved significantly. CONCLUSION: Contraception with desogestrel 75 μg resulted in a significantly improved quality of life and a reduction of migraine days over the observation period of 180 days. A clinically meaningful 30% reduction in pain was observed in 25/42 (60%) participants. For counselling reasons it is of importance, that the major reduction in migraine frequency occured during the initial 90 days, however further improvement occurs with longer duration of use. Prospective studies are needed to confirm these results. Springer Milan 2015-05-01 /pmc/articles/PMC4420760/ /pubmed/25933634 http://dx.doi.org/10.1186/s10194-015-0522-8 Text en © Merki-Feld et al.; licensee Springer. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
spellingShingle Research Article
Merki-Feld, Gabriele S
Imthurn, Bruno
Langner, Ronald
Seifert, Burkhardt
Gantenbein, Andreas R
Positive effects of the progestin desogestrel 75 μg on migraine frequency and use of acute medication are sustained over a treatment period of 180 days
title Positive effects of the progestin desogestrel 75 μg on migraine frequency and use of acute medication are sustained over a treatment period of 180 days
title_full Positive effects of the progestin desogestrel 75 μg on migraine frequency and use of acute medication are sustained over a treatment period of 180 days
title_fullStr Positive effects of the progestin desogestrel 75 μg on migraine frequency and use of acute medication are sustained over a treatment period of 180 days
title_full_unstemmed Positive effects of the progestin desogestrel 75 μg on migraine frequency and use of acute medication are sustained over a treatment period of 180 days
title_short Positive effects of the progestin desogestrel 75 μg on migraine frequency and use of acute medication are sustained over a treatment period of 180 days
title_sort positive effects of the progestin desogestrel 75 μg on migraine frequency and use of acute medication are sustained over a treatment period of 180 days
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4420760/
https://www.ncbi.nlm.nih.gov/pubmed/25933634
http://dx.doi.org/10.1186/s10194-015-0522-8
work_keys_str_mv AT merkifeldgabrieles positiveeffectsoftheprogestindesogestrel75mgonmigrainefrequencyanduseofacutemedicationaresustainedoveratreatmentperiodof180days
AT imthurnbruno positiveeffectsoftheprogestindesogestrel75mgonmigrainefrequencyanduseofacutemedicationaresustainedoveratreatmentperiodof180days
AT langnerronald positiveeffectsoftheprogestindesogestrel75mgonmigrainefrequencyanduseofacutemedicationaresustainedoveratreatmentperiodof180days
AT seifertburkhardt positiveeffectsoftheprogestindesogestrel75mgonmigrainefrequencyanduseofacutemedicationaresustainedoveratreatmentperiodof180days
AT gantenbeinandreasr positiveeffectsoftheprogestindesogestrel75mgonmigrainefrequencyanduseofacutemedicationaresustainedoveratreatmentperiodof180days